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Levetiracetam is a new anti-epileptic drug that is currently not licensed for use in children. Studies in adults suggest that it may
be a useful adjunctive treatment both in partial onset and generalised epilepsy. A retrospective case notes review of 26 children
age 10 years and under with refractory epilepsy was undertaken to evaluate the efficacy and safety of the drug. The drug appeared
to be most effective in children with partial onset seizures and least effective in those with myoclonic seizures. Sixty-one percent
of patients showed a good response to levetiracetam with at least a 50% reduction in seizure frequency with two of these 26
children with previously refractory epilepsy becoming seizure-free. Levetiracetam was also found to be well-tolerated with very
few reported side-effects.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
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INTRODUCTION
Levetiracetam (LEV), one of the newer-generation
anti-epileptic drugs (AEDs), is reported to have a
favourable pharmacokinetic profile, with rapid and al-
most complete oral absorption, nearly 100% bioavail-
ability, minimal plasma protein-binding and a low
incidence of both adverse side-effects and interactions
with other AEDs1, 2. These properties make the drug
a potentially useful adjunctive drug in the treatment
of children with chronic epilepsy. Currently, LEV is
only licensed for use in patients aged 16 years and
over with partial onset seizures, although published
data in teenagers and adults suggest that it is ef-
fective and well-tolerated as add-on therapy in both
generalised and partial epilepsy2–5.
To date, there are limited randomised clinical trial
(RCT) and open data on the use of LEV in young
children. This paper reviews retrospectively the use
of the drug in children aged 10 years or under in
a tertiary centre for paediatric epilepsy. The review
describes an open, clinical evaluation of the effec-
tiveness and safety of LEV and hopes to identify any
particular difficulties with its use in a group of infants
and young children with previously drug-resistant
epilepsy.
PATIENTS AND METHODS
Data were obtained from the computerised database
of the pharmacy department at the Royal Liverpool
Children’s Hospital (Alder Hey) over a 17-month
period (from November 2001 to March 2003). All
prescriptions were initiated or recommended by the
paediatric neurologists who supervise seizure or neu-
rology clinics both within the hospital but also in a
number of peripheral, peripatetic neurology clinics in
District General Hospitals.
Information was collected on the following: age
and sex of the children; seizure type; epilepsy syn-
drome; underlying cause (when known); presence or
absence of learning or physical difficulties; treatment
with other AEDs; dose of LEV (starting and maxi-
mum dose) and duration of treatment.
Efficacy was based on seizure frequency and du-
ration, with data obtained from seizure diaries com-
pleted by the child’s parents and carers. In the absence
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of seizure diaries, efficacy was more crudely deter-
mined by whether the child and their usual carers
considered that seizure frequency had improved. We
also attempted to assess the response of each seizure
type to LEV. Tolerability was assessed by document-
ing spontaneously-reported side effects by the child
or their carers.
Haematological and biochemical data, including
liver function and serum levels of LEV were not
obtained because these parameters are not measured
routinely in our patients with epilepsy.
The epilepsy syndromes were classified according
to the International League Against Epilepsy classifi-
cations of 1981 and 19896, 7.
Levetiracetam was always introduced in a once daily
regime with a starting dose of 10–15 mg/kg/day. Fur-
ther dose increases were undertaken in 10 mg/kg/day
increments every 2 weeks. The drug was available
in tablet form only (250 and 500 mg tablets). For
children who were unable to swallow the tablets
whole and for those with feeding gastrostomy
tubes, it was recommended that either a 250 or
500 mg tablet (depending on the age of the child)
was crushed and dissolved in either 5 or 10 ml of
water. The corresponding volume of suspension
would then be administered using either a syringe
or 5 ml measuring spoon, often in conjunction with
the child’s preferred juice or semi-solid food (e.g.
yoghourt).
RESULTS
Twenty-six patients aged 10 years and below were
prescribed levetiracetam during this period. The char-
acteristics of the patients are shown in Table 1.
The mean duration of follow up was eight (range,
1–30) months. The median age of the children in
this study was 7 years (range, 14 months–10 years).
The median number of AEDs previously tried in
these children was four (range, 1–9). Thirteen pa-
tients were receiving or had previously received,
non-AED treatments, including oral pyridoxine (eight
patients), piracetam (six patients—all because of fre-
quent myoclonus/myoclonic seizures), prednisolone
(five patients), intravenous immunoglobulins (one
patient), the ketogenic diet (one patient) and vagal
nerve stimulator (one patient).
The mean maintenance daily dose was 36.9 (range,
13.5–68.5) mg/kg/day. Information was only available
on 25 patients; body weight data were missing on one
patient. All 25 patients were simultaneously receiving
between one (15 patients), two (six patients) or three
(four patients) AEDs during their last clinic review.
The most commonly used adjunctive AEDs included
sodium valproate, lamotrigine, carbamazepine and one
Table 1: Demographic and clinical characteristics in the 26
patients.
Characteristic Number of
patients
Sex
Male 20
Female 6
Associated difficulties
Severe physical difficulties 15
Severe learning difficulties 17
Moderate learning difficulties 3
Autistic spectrum disorder 3
Epilepsy syndrome
West Syndrome 1
Lennox-Gastaut Syndrome 4
Symptomatic generalised epilepsy 10
Idiopathic generalised epilepsy 0
Cryptogenic partial epilepsy 2
Symptomatic partial epilepsy 9
Known aetiology
Cerebral palsy (spastic tetraplegia
or hemiplegia)
7
Cerebrovascular accident (temporal
lobe haemorrhage)
1
Cortical dysplasia 1
Angelman’s Syndrome 1
Lissencephaly 1
Alpers’ disease 1
Tuberous sclerosis 1
Septo-optic dysplasia 1
PEHO Syndrome 1
PEHO: progressive encephalopathy; edema; hypsarrhythmia;
optic atrophy.
of the benzodiazepines (in decreasing order, clobazam,
clonazepam, nitrazepam).
Of the 26 patients, 19 patients (73%) were expe-
riencing at least three seizure types and six patients
(23%), two seizure types. The response rates for each
seizure type following the introduction of LEV is
shown in Table 2.
Partial-onset seizures appeared to show the best re-
sponse; conversely, myoclonic seizures appeared to
show the worst response rate.
Three quarters (19 children) of our patients re-
mained on levetiracetam at the time of their last
clinic review with two of these patients report-
ing complete seizure-freedom (both with a history
of partial and secondarily generalised tonic–clonic
seizures). One of these patients was a 4-year-old
boy with Lennox-Gastaut Syndrome, maintained on
16.7 mg/kg/day of LEV in conjunction with lamotrig-
ine and the second was a 10-year-old boy with tuber-
ous sclerosis who was maintained on 13.5 mg/kg/day
of LEV in conjunction with carbamazepine. Fourteen
other patients reported a greater than 50% reduction
in seizure frequency, three patients experienced less
than 50% reduction, four showed no improvement and
three experienced a deterioration in seizure frequency.
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Table 2: Seizure type response to levetiracetam.
Seizure types Numbers Patients showing Percentage of
a >50% reduction in patients showing a >50%
seizure frequency response (%)
Myoclonic 14 4 28
Primary GTCS 9 5 55
Secondary GTCS 8 4 50
Absences 14 8 57
Partial onset 11 8 72
Infantile/epileptic spasmsa 7 5 71
Tonic 7 5 71
Atonic 2 2 100
Clonic 2 1 50
GTCS: generalised tonic–clonic seizures.
a Only one patient had spasms occurring in infancy (West Syndrome); this patient showed a 90% reduction in spasms; the other five
patients had epileptic spasms that developed after infancy.
Infantile spasms showed a 90% reduction in the one
patient with (cryptogenic) West Syndrome although
some partial seizures persisted; this patient received
a maintenance dose of 30 mg/kg/day.
The child with PEHO Syndrome (aged 2.5 years)
and the child with Alpers’ disease (aged 2 years)
showed no response to LEV and the drug was discon-
tinued after 6 and 9 weeks, respectively, due to lack of
effect. Both of these patients had daily partial, secon-
darily generalised tonic–clonic and absence seizures.
Overall, 61% of our patients showed a good re-
sponse to LEV with at least a 50% reduction in seizure
frequency. There did not appear to be any obvious
difference in response rates between specific epilep-
sies or epilepsy syndromes. Patients demonstrating
a greater than 50% reduction in seizures included
those with symptomatic generalised epilepsy (6 of 10
patients or 60%), symptomatic partial epilepsy (five
of nine, or 55%), cryptogenic partial (two of two),
Lennox-Gastaut Syndrome (two of four, or 50%) and
West Syndrome (one of one).
In three patients (aged 5–10 years), seizures dete-
riorated following the introduction of LEV; all three
demonstrated an increase in their pre-existing my-
oclonic seizures although in two of the three patients,
other seizure types appeared to show some improve-
ment. None of these patients received a dose in excess
of 35 mg/kg/day.
Only one patient reported one adverse effect whilst
receiving a dose of 35 mg/kg/day and this was exces-
sive sleepiness that necessitated discontinuation of the
drug. In four other patients (15% of the study group),
LEV was withdrawn because of seizure-deterioration
(three patients) and/or lack of effect (two patients).
DISCUSSION
This retrospective review of a group of young children
with refractory epilepsy suggests that levetiracetam
may be a useful adjunctive treatment in young children
with refractory epilepsy. In this population it appeared
to be most effective against partial onset seizures and
least effective for myoclonic seizures, with in some
patients, a deterioration in this specific seizure type.
It must be emphasised that our study population
is heterogeneous in terms of seizure type, epilepsy
syndrome, aetiology and additional neurological
(physical and learning) difficulties. It is therefore in-
appropriate to comment on the effectiveness of LEV
for specific epilepsy syndromes. In addition most pa-
tients had experienced and were continuing to expe-
rience multiple seizure types, that were both frequent
and that had proved resistant to at least five other
AEDs. The drug also appeared to be well-tolerated
and finally, the children’ carers had experienced no
obvious difficulty in administering the drug, despite
the lack of an infant or child-friendly preparation. In
this type of population it would perhaps be unreal-
istic to expect that a new AED would result in any
patient becoming seizure-free; a more realistic goal
would be to improve seizure control without causing
any serious adverse side-effects and possibly being
able to withdraw one or more any pre-existing AEDs.
Despite this understandably low expectation of suc-
cess, two of our previously refractory patients became
seizure-free and another 14 patients (53% of the en-
tire group) demonstrated a greater than 50% reduction
in seizure frequency. Furthermore, only one patient
developed an adverse side-effect (drowsiness) that
necessitated drug withdrawal and in seven patients
at least one other AED was able to be successfully
withdrawn, thereby reducing the AED ‘burden’ that
these young children were exposed to.
Wheless and Ng in an open-label study of 39 pae-
diatric patients with refractory epilepsy, found that
LEV was most effective against partial onset seizures
when used as add-on therapy8. In their study, 35%
of patients discontinued the drug due to lack of effi-
cacy or adverse effects. Lagae et al., who studied 21
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patients with refractory childhood epilepsies found
good overall efficacy of LEV for all seizure types,
with, in contrast to our findings, the best response in
those with myoclonic seizures9. The small numbers
of patients and heterogeneous nature of the different
study groups in terms of seizure types, epilepsy syn-
drome and aetiology may provide one explanation for
these apparently discrepant findings.
Three of our patients showed a transient deteriora-
tion in seizure frequency, all with an increase in my-
oclonic seizures, and with no obvious association with
either the initial dose or rate of titration of the drug.
Withdrawal of the drug resulted in a return to pre-LEV
levels. This effect has been reported recently—and
apparently more dramatically—with 18% of 44 chil-
dren demonstrating an exacerbation in seizure fre-
quency including convulsive and complex partial sta-
tus epilepticus and what the authors described as a
new seizure type, apnoeas10. Seizure-aggravation by
anti-epileptic drugs is a recognised phenomenon, par-
ticularly in children, and for which there are many po-
tential causes10, 11. Further, and more extensive clin-
ical experience will hopefully clarify this potentially
very important issue.
The present study has also shown that LEV appears
to be well-tolerated, at least in the short-term, with few
reported side-effects, similar to previous studies12, 13.
Somnolence has been reported as the most common
side-effect12, 13, and this was the only reason why one
of our patients was unable to tolerate the drug. None
of our patients reported any behavioural or psychiatric
effects, but it must be emphasised that the popula-
tion was small and largely comprised of children with
moderate, severe or profound learning difficulties, of-
ten in association with behavioural problems, which
may have masked any minor or subtle emotional or
frankly psychiatric side-effects.
Clearly, the study has a number of limitations, in-
cluding the relatively small and markedly heteroge-
neous population studied within a specialist centre,
the reliance on seizure diaries or carers’ often sub-
jective impressions to assess response and the lack of
long-term follow up data. It would therefore be in-
appropriate to provide any definite recommendations
on the precise use and role of LEV in young chil-
dren. Nevertheless, these preliminary findings of the
usefulness and practicality of using LEV in young
children, reflect ‘everyday’ clinical practice and may
be of some value. Larger prospective open-label stud-
ies with longer periods of follow up in homogeneous
epilepsy syndromes will be necessary to either con-
firm or refute this initial clinical experience. Finally,
it will be interesting to see whether further data on
patients with infantile spasms confirm (or refute) our
very preliminary findings, particularly following the
future introduction of LEV in a more infant-friendly
formulation (e.g. flavoured liquid or syrup or powder).
In conclusion, this small, retrospective review has
suggested that, at least in the short term, LEV may be
a useful adjunctive AED in children aged 10 years and
younger with chronic intractable epilepsy. The drug
appears to be most effective against partial seizures.
Finally, it seems to be well tolerated with very few
reported side effects.
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